Bausch + Lomb, Mimetogen deal

Mimetogen granted Bausch + Lomb an exclusive option to license exclusive, worldwide rights to develop and commercialize MIM-D3, a small molecule mimetic of nerve growth factor (NGF) that is in Phase...